Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Senotherapeutics for HIV and aging

Senotherapeutics for HIV and aging Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/03/2020 REVIEW URRENT PINION Matthew A. Szaniawski and Adam M. Spivak Purpose of review To summarize the state of chronic, treated HIV infection and its contribution to accelerated aging, and to evaluate recent research relevant to the study and treatment of aging and senescence. Recent findings Chronic treated HIV-1 infection is associated with significant risk of end-organ impairment, non-AIDS- associated malignancies, and accelerated physiologic aging. Coupled with the chronologic aging of the HIV- 1-positive population, the development of therapies that target these processes is of great clinical importance. Age-related diseases are partly the result of cellular senescence. Both immune and nonimmune cell subsets are thought to mediate this senescent phenotype, a state of stable cell cycle arrest characterized by sustained release of pro-inflammatory mediators. Recent research in the field of aging has identified a number of ‘senotherapeutics’ to combat aging-related diseases, pharmacologic agents that act either by selectively promoting the death of senescent cells (‘senolytics’) or modifying senescent phenotype (‘senomorphics’). Summary Senescence is a hallmark of aging-related diseases that is characterized by stable cell cycle arrest and chronic inflammation. Chronic HIV-1 infection predisposes patients to aging-related illnesses and is similarly marked by a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV & AIDS Wolters Kluwer Health

Loading next page...
 
/lp/wolters-kluwer-health/senotherapeutics-for-hiv-and-aging-X0hRIk0Msk

References (161)

Publisher
Wolters Kluwer Health
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000609
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/03/2020 REVIEW URRENT PINION Matthew A. Szaniawski and Adam M. Spivak Purpose of review To summarize the state of chronic, treated HIV infection and its contribution to accelerated aging, and to evaluate recent research relevant to the study and treatment of aging and senescence. Recent findings Chronic treated HIV-1 infection is associated with significant risk of end-organ impairment, non-AIDS- associated malignancies, and accelerated physiologic aging. Coupled with the chronologic aging of the HIV- 1-positive population, the development of therapies that target these processes is of great clinical importance. Age-related diseases are partly the result of cellular senescence. Both immune and nonimmune cell subsets are thought to mediate this senescent phenotype, a state of stable cell cycle arrest characterized by sustained release of pro-inflammatory mediators. Recent research in the field of aging has identified a number of ‘senotherapeutics’ to combat aging-related diseases, pharmacologic agents that act either by selectively promoting the death of senescent cells (‘senolytics’) or modifying senescent phenotype (‘senomorphics’). Summary Senescence is a hallmark of aging-related diseases that is characterized by stable cell cycle arrest and chronic inflammation. Chronic HIV-1 infection predisposes patients to aging-related illnesses and is similarly marked by a

Journal

Current Opinion in HIV & AIDSWolters Kluwer Health

Published: Mar 1, 2020

There are no references for this article.